Episode Details

#Retatrutide #GLP1 #WeightLoss #ObesityMedicine #metabolichealth 

Retatrutide is producing weight loss results we used to only see after bariatric surgery — but the medication is only half the story. In this video, Dr. Mohammed Paika (board-certified in internal medicine and obesity medicine) breaks down the five decisions he'd make before ever taking a first dose: how to find the right dose instead of chasing the highest one, why your heart rate and mood deserve the same attention as the scale, how to protect your muscle while the weight comes off, how to build a supplement plan instead of guessing, and why the medication should never be allowed to do all the work on its own.

Important: as of this video, retatrutide is still investigational and not yet FDA approved. Eli Lilly has completed three positive Phase 3 trials and plans to file for approval in Q1 2027. Right now it's accessible only through clinical trials or a narrow compassionate-use program — this video is the plan to have ready before that changes.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316

Timestamps 
0:00 – Intro
2:38 – Where Things Stand: Is Retatrutide FDA Approved?
4:35 – Rule 1: Dosing Is Not a Competition
10:37 – Rule 2: The Scale Doesn't See Everything (Heart + Mood)
16:50 – Rule 3: Muscle Is Not Optional
21:30 – Rule 4: Supplements Need a Strategy, Not a Guess
24:26 – Rule 5: Don't Let the Medication Do All the Work
28:15 – The Five Decisions That Actually Matter
29:18 – What To Do Next

References
TRIUMPH-1 phase 3 trial results (weight loss %, BMI outcomes, discontinuation rates) — https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
TRIUMPH-1 trial summary and safety profile — https://www.hcplive.com/view/retatrutide-weight-loss-endpoints-phase-3-obesity-trial
Retatrutide phase 2 data — mechanism and heart rate increase (~6.7 bpm), Doggrell, Expert Opinion on Investigational Drugs, 2023 — https://pubmed.ncbi.nlm.nih.gov/37947489/
FDA Drug Safety Communication — removal of suicidal ideation/behavior warning from GLP-1 receptor agonist labels (January 2026) — https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
Lilly TRIUMPH-2 and TRIUMPH-3 phase 3 results and planned Q1 2027 BLA submission — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Retatrutide access status, August 2026 — https://www.ajmc.com/view/lilly-expands-retatrutide-access-amid-doctor-pushback
Lean body mass loss data (SURMOUNT-1, STEP-1) and 2025 joint medical-society advisory — https://www.healio.com/news/endocrinology/20251114/muscle-matters-the-challenge-of-preserving-lean-mass-during-obesity-treatment
Fothergill et al., "Persistent metabolic adaptation 6 years after The Biggest Loser competition," Obesity, 2016 — https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538
American Medical Association's 2013 classification of obesity as a chronic disease — https://a